Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM Presented ByProf. Solange Peters, Lausanne University Hospital, Switzerland TrialPhase 3, CheckMate743 ConferenceESMO 2021 19 November, 2021 09:36
Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade) ConferenceESMO 2020 25 November, 2020 12:45
Thoracic cancers versus COVID-19 Presented ByLeora Horn, Vanderbilt-Ingram Cancer Center, USA TrialTERAVOLT ConferenceASCO 2020 28 August, 2020 14:50
Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma Presented ByDr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK TrialPROMISE-meso ConferenceESMO 2019 26 November, 2019 23:04
CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days ConferenceWCLC 2019 8 November, 2019 17:05
Novel targets in mesothelioma may aid in developing treatment strategies TrialPhase 2, ADAM ConferenceWCLC 2019 8 November, 2019 09:11
Unmet needs in surgical management of malignant pleural mesothelioma Presented ByDr Valerie Rusch, Dr Harvey Pass, 21 November, 2018 23:31